12:00 AM
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Influenza Vaccine Enhancement Patch: Phase I data

An open-label, European Phase I trial in 300 healthy volunteers showed that the Influenza VEP in combination with GlaxoSmithKline's H5N1 antigen did not produce a >=2 fold increase in HAI titers vs. GSK's licensed Pumarix H5N1 vaccine. However, VEP plus the...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >